School of Medicine


Showing 71-80 of 175 Results

  • Andrey Finegersh, MD, PhD

    Andrey Finegersh, MD, PhD

    Assistant Professor of Otolaryngology - Head & Neck Surgery (OHNS)

    BioDr. Finegersh is a fellowship-trained head and neck surgical oncologist with board certification in otolaryngology and a clinical assistant professor with the Stanford School of Medicine Department of Otolaryngology.

    He specializes in treatment of benign and malignant tumors of the head and neck and has received additional training in microvascular reconstruction and transoral robotic surgery. He takes tremendous pride in providing compassionate care for patients and managing challenging diagnoses.

    Dr. Finegersh completed his MD and PhD degrees at the University of Pittsburgh School of Medicine's combined Medical Scientist Training Program. He went on to complete residency in otolaryngology at the University of California San Diego (UCSD) and his fellowship at Stanford University, where he stayed on as faculty.

    He has extensive research experience in head and neck cancer epigenetics and completed post-doctoral research at the University of Pittsburgh and UCSD. He has received grants from the NIH and American Academy of Otolaryngology and has an active research lab studying molecular mechanisms of cancer. Dr. Finegersh has additional clinical interests in studying the role of minimally invasive surgery to improve outcomes for head and neck cancer patients.

  • Anna Finley Caulfield, MD

    Anna Finley Caulfield, MD

    Clinical Professor, Neurology & Neurological Sciences

    Current Research and Scholarly InterestsDr. Finley joined the Stanford Stroke Center in 2004 from Beth Israel Deaconess Medical Center in Boston. She cares for acute stroke patients and other neurologically critical ill patients in the intensive care unit. Currently, her research interests include hypothermia after cardiac arrest and comparing health care provider's predications of future neurological function in neurologically critical ill patients to their 6-month outcome.

  • David Fiorentino, MD, PhD

    David Fiorentino, MD, PhD

    Professor of Dermatology

    Current Research and Scholarly InterestsI am interested in all types of immune-mediated skin disease, with a focus on psoriasis and rheumatic skin disease. I co-direct a multi-disciplinary clinic dedicated to the care of patients with rheumatic skin diseases, such as lupus erythematosus, vasculitis, dermatyositis and scleroderma. I conduct multiple clinical trials and I participate in translational research with tissues obtained from a prospective cohort of patients with scleroderma, lupus, and dermatomyositis.

  • Andrew Fire

    Andrew Fire

    George D. Smith Professor of Molecular and Genetic Medicine and Professor of Pathology and of Genetics

    Current Research and Scholarly InterestsWe study natural cellular mechanisms for adapting to genetic change. These include systems activated during normal development and those for detecting and responding to foreign or unwanted genetic activity. Underlying these studies are questions of how a cells can distinguish information as "self" versus "nonself" or "wanted" versus "unwanted".

  • Michael Fischbach

    Michael Fischbach

    Liu (Liao) Family Professor

    Current Research and Scholarly InterestsThe microbiome carries out extraordinary feats of biology: it produces hundreds of molecules, many of which impact host physiology; modulates immune function potently and specifically; self-organizes biogeographically; and exhibits profound stability in the face of perturbations. Our lab studies the mechanisms of microbiome-host interactions. Our approach is based on two technologies we recently developed: a complex (119-member) defined gut community that serves as an analytically manageable but biologically relevant system for experimentation, and new genetic systems for common species from the microbiome. Using these systems, we investigate mechanisms at the community level and the strain level.

    1) Community-level mechanisms. A typical gut microbiome consists of 200-250 bacterial species that span >6 orders of magnitude in relative abundance. As a system, these bacteria carry out extraordinary feats of metabolite consumption and production, elicit a variety of specific immune cell populations, self-organize geographically and metabolically, and exhibit profound resilience against a wide range of perturbations. Yet remarkably little is known about how the community functions as a system. We are exploring this by asking two broad questions: How do groups of organisms work together to influence immune function? What are the mechanisms that govern metabolism and ecology at the 100+ strain scale? Our goal is to learn rules that will enable us to design communities that solve specific therapeutic problems.

    2) Strain-level mechanisms. Even though gut and skin colonists live in communities, individual strains can have an extraordinary impact on host biology. We focus on two broad (and partially overlapping) categories:

    Immune modulation: Can we redirect colonist-specific T cells against an antigen of interest by expressing it on the surface of a bacterium? How do skin colonists induce high levels of Staphylococcus-specific antibodies in mice and humans?

    Abundant microbiome-derived molecules: By constructing single-strain/single-gene knockouts in a complex defined community, we will ask: What are the effects of bacterially produced molecules on host metabolism and immunology? Can the molecular output of low-abundance organisms impact host physiology?

    3) Cell and gene therapy. We have begun two new efforts in mammalian cell and gene therapies. First, we are developing methods that enable cell-type specific delivery of genome editing payloads in vivo. We are especially interested in delivery vehicles that are customizable and easy to manufacture. Second, we have begun a comprehensive genome mining effort with an emphasis on understudied or entirely novel enzyme systems with utility in mammalian genome editing.

  • Michael Fischbein

    Michael Fischbein

    Thelma and Henry Doelger Professor of Cardiovascular Surgery

    Current Research and Scholarly InterestsMolecular and genetic mechanisms of aortic aneurysm/dissection development. Molecular mechanisms of aneurysm formation in Marfan Syndrome. Clinical research interests include thoracic aortic diseases (aneurysms, dissections).